Scientific Advisors

Prof. Sir Chris Dobson
(In Memoriam)
Prof. Sir Chris Dobson
(In Memoriam)

FRS FMedSci, John Humphrey Plummer Professor of Chemical and Structural Biology at the University of Cambridge and Master of St John’s College, Cambridge

Remembering Sir Chris Dobson (1949-2019)

Professor Sir Chris Dobson was the John Humphrey Plummer Professor of Chemical and Structural Biology at the University of Cambridge and Master of St John’s College, Cambridge. He co-founded the Cambridge Centre for Misfolding Diseases and served as Vice-Chairman of the board of WaveBreak. Professor Sir Chris Dobson was a Fellow of the Royal Society (FRS) and of the Academy of Medical Sciences (FMedSci), and a Foreign Associate of the US National Academy of Sciences. He was the recipient of many honours including the Royal Medal by the Royal Society (2009), the Heineken Prize for Biochemistry and Biophysics (2014) and the Feltrinelli International Prize for Medicine (2014). In 2018, he was awarded a Knighthood by the Queen. He was one of the world’s leading scientists working at the interface of the physical and biological sciences. His work had led to the discovery of fundamental principles that determine the aberrant self-association of protein molecules, and the manner in which such behaviour can give rise to a multitude of human diseases, including Alzheimer’s and Parkinson’s diseases. He made very significant contributions to our fundamental understanding of how and why proteins are in most cases able to fold correctly to generate normal biological function, yet in certain circumstances misfold and drive a wide range of diseases. He developed entirely novel biophysical and biochemical approaches for this purpose, and he deployed these techniques to unravel the molecular basis of these highly complex processes.

Nora Bengoa-Vergniory, PhD
ALPHA-SYNUCLEIN AGGREGATION IN PARKINSON’S DISEASE
Nora Bengoa-Vergniory, PhD
ALPHA-SYNUCLEIN AGGREGATION IN PARKINSON’S DISEASE

Nora Bengoa-Vergniory’s research focuses on alpha-synuclein aggregation and neuroinflammation in neurodegeneration, specifically in Parkinson’s and Alzheimer’s diseases. Although it is known that aggregation and neuroinflammation are key features of Parkinson’s and Alzheimer’s disease progression, many unanswered questions persist. Where does the aggregation begin? How does it spread? Which cells respond to it? How do they respond? And, importantly, how can we prevent these processes? Dr. Bengoa-Vergniory’s laboratory leverages genetic models, patient-derived induced pluripotent stem (iPS) cells, human tissue, and PLA-based assays for the detection of early aggregation to provide novel insights into the role of aggregation and glial activation in Parkinson’s and Alzheimer’s diseases. In 2022, Dr. Bengoa-Vergniory established her research laboratory at Achucarro Basque Center for Neuroscience, Spain, with the support of Ikerbasque, IBRO, MJFF, and the Spanish Ministry for Science and Innovation while remaining a Research Visitor at Oxford University. She completed her PhD in 2014 at the University of the Basque Country, where she studied the role of Wnt signaling during early neuronal differentiation in human stem cell models. Dr. Bengoa-Vergniory joined the Wade-Martins laboratory at Oxford University in 2015 for her postdoctoral training on the role of alpha-synuclein aggregation in Parkinson’s disease. In 2018, she became an Oxford-BMS/Celgene Research Fellow studying alpha-synuclein aggregation and glial activation in Parkinson’s. Through the years, she has been supported generously by MJFF, ARUK, PDUK, the Guarantors of Brain, the Center of Excellence in Neuroscience, BMS, Ikerbasque, IBRO, the Basque Government, and the Spanish Ministry for Science and Innovation.

Pat Connelly, PhD
BIOPHYSICS & PROTEIN REGULATION
Pat Connelly, PhD
BIOPHYSICS & PROTEIN REGULATION

Pat Connelly is a biophysics expert who created and led a number of specialized R&D business units at Vertex Pharmaceuticals, where he was a founding scientist and former employee. He established the unique Materials Discovery & Characterization development function at Vertex, where he, his staff, and colleagues co-invented three first-in-class medicines—INCIVEK® for hepatitis C, and KALYDECO® and ORKAMBI® for cystic fibrosis. Dr. Connelly also co-founded and led Vertex’s Corporate Innovation unit that catalyzed the company’s entry into sickle cell disease and was a member of the Vertex-CRISPR Therapeutics Joint Research Committee that brought forth Exa-cel, one of the first gene-editing medicines to be tested in humans, currently in Phase 3 clinical trials.

Jeffrey L. Cummings, MD, ScD
ALZHEIMER’S DISEASE RESEARCH, DEVELOPMENT, & CLINICAL TRIALS
Jeffrey L. Cummings, MD, ScD
ALZHEIMER’S DISEASE RESEARCH, DEVELOPMENT, & CLINICAL TRIALS

Jeffrey Cummings, MD, ScD, is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas (UNLV). Dr. Cummings is globally recognized for his contributions to Alzheimer’s research, drug development, and clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017), the Distinguished Scientist Award of the American Association of Geriatric Psychiatry (2010), the Leadership and Achievement Award by the International Society of CNS Drug Development (2018), the Bengt Winblad Lifetime Achievement Award from the Alzheimer’s Association (2019), the International Psychogeriatric Association Distinguished Service Award (2019), and the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize. He was featured in the GQ (formerly Gentleman’s Quarterly) June 2009 issue as a “Rock Star of Science™.”  Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. He was formerly Augustas Rose Professor of Neurology and Professor of Psychiatry at UCLA, Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. Dr. Cummings is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. He has authored or edited 43 books and published more than 800 peer-reviewed papers. Dr. Cummings completed a Neurology residency and a Fellowship in Behavioral Neurology at Boston University followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London.

Bradley Hyman, MD, PhD
NEUROPATHOPHYSIOLOGIC & GENETIC FACTORS UNDERLYING DEMENTIA
Bradley Hyman, MD, PhD
NEUROPATHOPHYSIOLOGIC & GENETIC FACTORS UNDERLYING DEMENTIA

Bradley Hyman is the John B. Penney, Jr. Professor of Neurology at Harvard Medical School and Massachusetts General Hospital and the Director of the Massachusetts Alzheimer’s Disease Research Center at the MassGeneral Institute for Neurodegenerative Disease (MIND). His laboratory studies the anatomical and molecular basis of dementia in Alzheimer’s disease and dementia with Lewy bodies. Dr. Hyman has received the Metropolitan Life Award, the Potamkin Prize, a National Institute on Aging Merit award, and an Alzheimer Association Pioneer Award. He received his MD and PhD from University of Iowa.

David Klenerman, PhD
PROTEIN PHYSICAL CHEMISTRY
David Klenerman, PhD
PROTEIN PHYSICAL CHEMISTRY

David Klenerman is a Royal Society Glaxo Wellcome Professor of Molecular Medicine at the University of Cambridge, where he develops and applies physical methods to biological and biomedical problems, with particular focus on laser spectroscopy and single-molecule fluorescence. He is a co-inventor of Solexa next-generation DNA sequencing methodology. Previously, he was a professor at the Department of Chemistry, University of Cambridge after working for seven years for BP Research in the Laser Spectroscopy Group. Dr. Klenerman is a Fellow of the Royal Society and the Academy of Medical Sciences. He was awarded the Royal Medal from the Royal Society in 2018 and the Millennium Technology Prize in 2020, both jointly with Shankar Balasubramanian;, and he was awarded the 2022 Breakthrough Prize for Life Sciences jointly with Shankar Balasubramanian and Pascal Mayer. He was knighted in 2019. Dr. Klenerman completed his PhD at Cambridge University working with Professor Ian Smith on infra-red chemiluminescence, and he completed postdoctoral research at Stanford University with Professor Dick Zare on high overtone chemistry.

Edward B. Lee, MD, PhD
TDP-43 Mediated Neurodegeneration, ALS, Alzheimer's Disease, & Frontotemporal Dementia (FTD)
Edward B. Lee, MD, PhD
TDP-43 Mediated Neurodegeneration, ALS, Alzheimer's Disease, & Frontotemporal Dementia (FTD)

Dr. Lee is an Associate Professor of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine, Co-Director of the Institute on Aging, Director of the Center for Neurodegenerative Disease Research Brain Bank, and Associate Director of the Penn Alzheimer’s Disease Research Center. His research aims to uncover molecular mechanisms that contribute to the formation or resolution of neurodegenerative disease proteinopathies using a multidisciplinary approach spanning basic biochemistry and structural biology to cellular and in vivo models and human neuropathology. Dr. Lee’s team focuses on the genetic and environmental factors that influence human neuropathology and translates these findings into tractable experimental models—for example, uncovering how pathogenic variants in ATPase valosin-containing protein (VCP) lead to autosomal dominant tau and TDP-43 proteinopathies. Dr. Lee obtained his MD and PhD degrees followed by clinical training in neuropathology at the University of Pennsylvania.

Kelvin Luk, PhD, MTR
BIOLOGY AND PATHOGENESIS OF ALPHA-SYNUCLEINOPATHIES
Kelvin Luk, PhD, MTR
BIOLOGY AND PATHOGENESIS OF ALPHA-SYNUCLEINOPATHIES

Kelvin Luk is Research Associate Professor of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine and the Penn Center for Neurodegenerative Disease Research (CNDR). His research aims to untangle the relationship between the formation of alpha-synuclein pathology that characterizes Parkinson’s disease and related disorders [e.g., dementia with Lewy bodies and multiple system atrophy (MSA)] as well as its contribution to neuronal dysfunction and degeneration. Using a multidisciplinary approach spanning in vitro, cell-based, and in vivo models, Dr. Luk’s team has been revealing the mechanisms by which this protein misfolds into pathological agents that self-propagate and transmit between cells. His group developed several novel cell- and animal-based models of synucleinopathy that are widely used in the field. This knowledge base has also been leveraged toward developing innovative tools for detecting neurodegeneration-related proteins and to evaluate emerging therapies for neurodegenerative disorders. Dr. Luk received his PhD from McGill University and completed his postdoctoral training at the University of Pennsylvania.

Rajesh Pahwa, MD
CLINICAL TRIALS FOR PARKINSON’S DISEASE THERAPEUTICS
Rajesh Pahwa, MD
CLINICAL TRIALS FOR PARKINSON’S DISEASE THERAPEUTICS

Rajesh Pahwa is the Laverne and Joyce Rider Professor of Neurology, Chief of the Parkinson’s and Movement Disorder Division, and Director of Parkinson Foundation Center of Excellence at the University of Kansas Medical Center. Dr. Pahwa joined the faculty of the Department of Neurology as an instructor in 1992 and was named the inaugural recipient of the Laverne and Joyce Rider Professorship in 2005. Dr. Pahwa is also a Diplomate of the American Board of Psychiatry and Neurology, and he directs the Parkinson’s Disease and Movement Disorder Center at The University of Kansas Health System. Dr. Pahwa’s research focuses on the various aspects of Parkinson’s disease and essential tremor, and he is currently involved in studies related to medical and surgical forms of therapies for Parkinson’s disease and essential tremor. In addition to publishing more than 250 peer-reviewed articles, chapters, and abstracts in leading neurology and movement disorder journals, he has conducted more than 150 clinical trials related to Parkinson’s disease and other movement disorders. Dr. Pahwa is the co-editor of Handbook of Parkinson’s Disease (3rd and 4th editions), Therapy of Parkinson’s Disease (3rd edition), and Handbook of Essential Tremor and other Tremor Disorders. He also is co-author of the book, Parkinson’s Disease: Questions and Answers (4th edition). Dr. Pahwa received his M.B.B.S. (M.D.) degree at Seth G.S. Medical College, University of Bombay, India. He completed an internship in medicine followed by a residency in Neurology, both at Baylor College of Medicine. He then completed a one-year fellowship in movement disorders at the University of Kansas Medical Center.

Executive Leadership

Bart Henderson
PRESIDENT & CHIEF EXECUTIVE OFFICER
Bart Henderson
PRESIDENT & CHIEF EXECUTIVE OFFICER

Bart Henderson is President and Chief Executive Officer of WaveBreak. Mr. Henderson brings extensive experience in company-building and developing innovative medicines. Previously, he was operating partner at Flagship Pioneering, where he led the build-out of Harbinger Health, developing a multi-cancer early-detection platform with leading-edge artificial intelligence and machine-learning technologies. Prior to Flagship, he was CEO and co-founder of Torque (now Repertoire Immune Medicines) where, under his leadership, the company significantly advanced its cellular immunotherapy pipeline, initiating the company’s first clinical trial, receiving Fast Track designation from the FDA, and building a state-of-the-art manufacturing facility for Torque’s T cell immunotherapies. Bart was founder and president of Rhythm and its subsidiary, Motus, where he acquired and completed successful Phase II clinical trials for two metabolic disease therapeutics: Imcivree™, which was granted Breakthrough Designation and is the first drug approved in the U.S. for genetic obesity; and relamorelin, which was acquired by Allergan (with Motus). He was a founding employee and chief business officer of Radius, where he built the pipeline, acquiring Tymlos™, now approved for the treatment of osteoporosis, and acquiring Orserdu™, now approved for the treatment of metastatic breast cancer. Previously, he was an entrepreneur-in-residence at MPM Capital. He led business development at Microbia (now Ironwood Pharmaceuticals) and was head of sales and marketing at Vertex, which launched its first product and significantly expanded its pipeline during his tenure. Mr. Henderson previously held marketing management positions at Amgen and Merck. He received an MBA from Dartmouth’s Tuck School of Business and a BA from Amherst College.

Bochong Li, PhD
VICE PRESIDENT, INNOVATION
Bochong Li, PhD
VICE PRESIDENT, INNOVATION

Bochong Li is Vice President, Innovation at WaveBreak, with responsibility for science, technology platform, and company-building strategy as well as leading initiatives in external collaboration. Prior to joining WaveBreak, Dr. Li was Senior Director of Strategy and Innovation at Cullinan Oncology, an investing and drug development company focused on oncology assets. As part of the founding team and through the company’s IPO, Dr. Li was responsible for investment identification, due diligence, business development, and internal new asset creation and was an inventor on multiple patents including multi-specific T cell engagers and cytokine fusion constructs. Dr. Li started his career at MPM Capital, where he led initiatives in company creation in synthetic biology and living medicine. Dr. Li holds a Juris Doctor degree from Harvard Law School and a PhD in Biomedical Engineering from Duke University, where he also received his BSE magna cum laude in Biomedical Engineering and Mathematics.

David Witter, PhD
Vice President, Drug Discovery
David Witter, PhD
Vice President, Drug Discovery

David Witter is Vice President, Drug Discovery at WaveBreak. Prior to joining WaveBreak, Dr. Witter was Vice President, Drug Discovery at Sail Bio, where he led scientific and business strategies for the development of novel small-molecule therapeutics for rare kidney diseases. Previously, as Vice President, Preclinical Research Drug Discovery at Cullinan Oncology, he focused on the development of small-molecule oncology therapeutics, including Zipalertinib, an EGFR inhibitor with Breakthrough Designation currently in clinical trials. Prior to his position with Cullinan Oncology, Dr. Witter led cross-functional drug discovery teams at Merck focused on small-molecule therapeutics for neurodegenerative diseases, rheumatoid arthritis, and oncology. Dr. Witter’s earlier positions include leading drug discovery programs at Aton Pharma (acquired by Merck) for Zolinza, the first HDAC inhibitor on the global market; OSI Pharmaceuticals focused on diabetes; and Cadus Pharmaceutical discovering signal transduction modulators for asthma and inflammation. Dr. Witter is the co-author of 25+ scientific publications and co-inventor of 60+ patents. He obtained his PhD in Organic Chemistry with John C. Vederas at the University of Alberta. During his postdoctoral fellowship at the University of Utah with C. Dale Poulter, Dr. Witter’s research led to the characterization of a yeast protein prenyltransferase (PGGTase-II). He earned his BS in Organic Chemistry at the University of Waterloo.

Mike Dey, PhD
Head of Manufacturing and Technical Operations
Mike Dey, PhD
Head of Manufacturing and Technical Operations

Mike Dey is Head of Manufacturing and Technical Operations at WaveBreak, responsible for development of chemical and drug product processes, production, quality control & assurance, and clinical supply to support the WaveBreak portfolio. He brings extensive experience in development, industrialization, and manufacturing innovative medicines, with more than 40 NDA/BLA approvals. Previous to joining WaveBreak, Dr. Dey held senior R&D, manufacturing, and commercial positions at large and small pharmaceutical companies as well as start-up companies, including 10 years leading his own consulting company supporting multiple clients in these areas. He was Vice President, Pharmaceutical Development and Vice President, Endocrinology Strategy team at Ipsen, where he supported Somatuline in becoming a $1 billion product as well as multiple out-licensing partnerships on early products that are now approved life-changing therapies. Dr. Dey held senior manufacturing and R&D positions in Aventis (now Sanofi) in various mergers, including Fisons and RPR, for which he led integration of industrialization and R&D teams to accelerate new products, including delivery systems such as SoloStar. He has developed novel equipment and built facilities in the U.S., EU, and Asia to secure supply from earliest clinical trials to global launches. Dr. Dey has led both multisite global organizations and “virtual,” fully outsourced operations with a global network of development and manufacturing partners, from early research through all clinical stages and regulatory approvals, with multiple successful FDA pre-approval inspections. He is an inventor of multiple formulation and drug delivery patents supporting several approved products. Dr. Dey has a BSc in Pharmacy and a PhD in Pharmaceutical Technology/Engineering from Robert Gordon University, UK.

Board of Directors

G. Kelly Martin
CHAIRMAN
G. Kelly Martin
CHAIRMAN

Kelly Martin is Chairman of WaveBreak Therapeutics. He served as Chief Executive Officer of Radius Health, Inc., from 2020 until its acquisition by Gurnet Point Capital and Patient Square Capital in 2022. From 2003 to 2013, Mr. Martin was CEO of Elan Corporation plc, a pharmaceutical company focused on neurodegenerative diseases such as multiple sclerosis, Alzheimer’s, and Parkinson’s. Headquartered in Ireland, Elan operated globally and maintained several strategic partnerships including Biogen Idec and Johnson & Johnson. The company was sold to Perrigo Company plc in 2013 for more than $8.6 billion in stock and cash. Mr. Martin’s professional career started in finance having spent 22 years at Merrill Lynch & Co. Inc., leading several global divisions including Debt markets, International Equities, Systems & Technology, and the International Private Banking Group. While at Merrill Lynch, Mr. Martin lived and worked in New York, Tokyo, and London.

Bart Henderson
PRESIDENT & CHIEF EXECUTIVE OFFICER
Bart Henderson
PRESIDENT & CHIEF EXECUTIVE OFFICER

Bart Henderson is President and Chief Executive Officer of WaveBreak. Mr. Henderson brings extensive experience in company-building and developing innovative medicines. Previously, he was operating partner at Flagship Pioneering, where he led the build-out of Harbinger Health, developing a multi-cancer early-detection platform with leading-edge artificial intelligence and machine-learning technologies. Prior to Flagship, he was CEO and co-founder of Torque (now Repertoire Immune Medicines) where, under his leadership, the company significantly advanced its cellular immunotherapy pipeline, initiating the company’s first clinical trial, receiving Fast Track designation from the FDA, and building a state-of-the-art manufacturing facility for Torque’s T cell immunotherapies. Bart was founder and president of Rhythm and its subsidiary, Motus, where he acquired and completed successful Phase II clinical trials for two metabolic disease therapeutics: Imcivree™, which was granted Breakthrough Designation and is the first drug approved in the U.S. for genetic obesity; and relamorelin, which was acquired by Allergan (with Motus). He was a founding employee and chief business officer of Radius, where he built the pipeline, acquiring Tymlos™, now approved for the treatment of osteoporosis, and acquiring Orserdu™, now approved for the treatment of metastatic breast cancer. Previously, he was an entrepreneur-in-residence at MPM Capital. He led business development at Microbia (now Ironwood Pharmaceuticals) and was head of sales and marketing at Vertex, which launched its first product and significantly expanded its pipeline during his tenure. Mr. Henderson previously held marketing management positions at Amgen and Merck. He received an MBA from Dartmouth’s Tuck School of Business and a BA from Amherst College.

Owen Hughes
NON-EXECUTIVE DIRECTOR
Owen Hughes
NON-EXECUTIVE DIRECTOR

Owen Hughes is the Chief Executive Officer of Cullinan Oncology and an Executive Partner at MPM Capital. Prior to joining Cullinan and MPM, Mr. Hughes served as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, where he was responsible for financing, M&A, business development and operations. He led several licensing and M&A transactions, including a long term partnership with the Bill & Melinda Gates Foundation, and raised approximately $1.8 billion in private capital. Prior to Intarcia, Mr. Hughes served as a Director of Brookside Capital, a hedge fund under the Bain Capital umbrella, managing public and private healthcare investments. Prior to his tenure at Brookside, he was Senior Portfolio Manager at Pyramis Global Advisors, a Fidelity Investments Company. Owen has more than 16 years of Wall Street experience, on both the buy and sell-side. Mr. Hughes received his BA from Dartmouth College. Mr. Hughes currently serves on the Board of Directors of Radius Health (NASDAQ: RDUS) and Translate Bio (NASDAQ: TBIO).

Andrew von Eschenbach, MD
NON-EXECUTIVE DIRECTOR
Andrew von Eschenbach, MD
NON-EXECUTIVE DIRECTOR

Andrew von Eschenbach was appointed acting Commissioner of the U.S. Food and Drug Administration in 2005, was later confirmed by the Senate as Commissioner in 2006, and then held the role until his resignation in 2009. Prior to that, Dr. von Eschenbach served as director of the National Cancer Institute at the National Institutes of Health from 2002 to 2006. Dr. von Eschenbach also previously served as a physician, surgeon, oncologist and executive, from Chairman of the Department of Urologic Oncology to Executive Vice President and Chief Academic Officer at the University of Texas M.D. Anderson Cancer Center from 1976 until 2002, and since 2009, he has continued to serve as an adjunct professor there. Dr. von Eschenbach also currently serves on the Board of Directors of Bausch Health plc, as president of Samaritan Health Initiative, senior fellow at the Bipartisan Policy Centre, and as a senior fellow at the Milken Institute. In 2006, Dr. von Eschenbach was named to the “Time 100,” the magazine’s annual list of the 100 most influential people to shape the world. Additionally, Dr. von Eschenbach was selected in both 2007 and 2008 as one of the Modern Healthcare/Modern Physician’s “50 Most Powerful Physician Executives in Healthcare.” Dr. von Eschenbach is the author of more than 300 scientific articles and studies.

Fiona Dunlevy
NON-EXECUTIVE DIRECTOR
Fiona Dunlevy
NON-EXECUTIVE DIRECTOR

Fiona Dunlevy has served as Company Secretary of Malin plc (ISE:MLC), a publicly listed company investing in highly innovative life sciences companies, since September 2018, prior to which she was Head of Tax from 2015. Before joining Malin, Fiona worked at Elan Corporation plc and with Deloitte’s international tax group in Dublin and New York. Fiona is an associate of the Irish Taxation Institute and of Chartered Accountants Ireland.

John P. Butler
NON-EXECUTIVE DIRECTOR
John P. Butler
NON-EXECUTIVE DIRECTOR

John Butler is President and Chief Executive Officer of Akebia. Prior to joining Akebia, from 2011 until 2013, Mr. Butler served as Chief Executive Officer of Inspiration Biopharmaceuticals, where led transactions that resulted in the sale of its hemophilia assets to Cangene Corporation and Baxter International for total aggregate consideration that could exceed $1 billion. From 1997 to 2011, Mr. Butler held various positions at Genzyme Corporation (now Sanofi Genzyme), most recently serving as President of the company’s rare genetic diseases business. From 2002 until 2010, Mr. Butler led Genzyme’s renal division. Prior to his work at Genzyme, Mr. Butler held sales and marketing positions at Amgen and Hoffmann-La Roche. He currently also serves on the Board of Directors of Zynerba Pharmaceuticals and is a former director of Relypsa and former director and chairman of the board of Keryx. Mr. Butler is Chair of Kidney Care Partners and formerly served as a Chairman of the Board of Trustees of the American Kidney Fund. Mr. Butler received a BA in Chemistry from Manhattan College and an MBA from Baruch College, City University of New York.

Back to Top